Some research suggests that SGLT-2 inhibitors may influence atherosclerotic risk factors and pathways involved in both the acute and late stages of stroke, indicating a broader impact on cerebrovascular health [12]. The gene discussed is SLC5A2; the disease is stroke disorder.